Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists test tracer to see Cells' 'Battery' in real time

NCT ID NCT07506616

First seen Apr 18, 2026 · Last updated Jun 22, 2026 · Updated 13 times

Summary

This early study tests a new radioactive tracer called 18F-TPP to see if it can map the energy levels inside cells using PET scans. Researchers will study 24 healthy adults to understand how the tracer moves through the body and develop methods to measure cell membrane potential. This is a first step toward better imaging of cell health, not a treatment study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MEMBRANE POTENTIAL MAPPING are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Yale University PET Center

    New Haven, Connecticut, 06510, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

18F-TPP (a radioactive tracer for PET imaging)

What this could lead to

If successful, this could provide a new way to see cell health in the body, which may help study diseases like heart or brain conditions.

What could go wrong

This is a very early Phase 1 study with only 24 healthy volunteers. It is designed to test the imaging method, not to treat any illness, so it may not lead to direct patient benefits.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.